Liposomal Doxorubicin Market Report 2026

The liposomal doxorubicin market size has grown strongly in recent years. It will grow from $1.32 billion in 2025 to $1.41 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to limitations of conventional doxorubicin toxicity, increasing global cancer incidence, early adoption of liposomal drug delivery, expansion of oncology treatment protocols, growing hospital-based chemotherapy administration.

The liposomal doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising demand for safer cancer therapies, increasing focus on patient quality of life, expansion of oncology treatment access in emerging markets, growth in liposomal drug development pipelines, increasing approvals of generic oncology drugs. Major trends in the forecast period include growing preference for targeted chemotherapy formulations, increasing use of liposomal drugs to reduce cardiotoxicity, rising adoption in ovarian and breast cancer treatment, expansion of generic liposomal doxorubicin products, growing demand for improved drug tolerability in oncology.

The increasing incidence of cancer is anticipated to drive the growth of the liposomal doxorubicin market in the coming years. Cancer is a group of diseases that can arise in nearly any organ or tissue when abnormal cells grow uncontrollably, breach their normal boundaries, and either metastasize to other organs or invade surrounding tissues. The rise in cancer cases is attributed to factors such as an aging population, lifestyle modifications, environmental exposures, and advancements in diagnostic technologies. Liposomal doxorubicin is employed in cancer therapy to enhance drug delivery to tumors, minimize toxicity, and improve treatment outcomes. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization advocating for cancer awareness, reported that cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, marking a growth of 2.19%. Consequently, the rising cancer prevalence is fueling the expansion of the liposomal doxorubicin market.

Key players in the liposomal doxorubicin market are concentrating on developing innovative liposomal injectable formulations, such as ready-to-use liposomal doxorubicin products, to improve the therapeutic index, lower systemic toxicity, and streamline hospital administration compared with traditional free-drug doxorubicin infusions. Liposomal doxorubicin is a nanoparticle-encapsulated formulation in which doxorubicin is enclosed within lipid bilayer vesicles (liposomes) that modify pharmacokinetics and biodistribution. Its main characteristics include extended circulation time, preferential tumor targeting via the enhanced permeability and retention (EPR) effect, reduced cardiotoxicity, altered tissue exposure compared with non-encapsulated doxorubicin, and compatibility with combination therapies. For instance, in July 2024, ForDoz Pharma Corp., a US-based specialty pharmaceutical company, received FDA approval for DOXOrubicin Hydrochloride Liposome Injection in ready-to-use 20 mg/10 mL and 50 mg/25 mL presentations for ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma (with bortezomib). The liposomal formulation enables sustained, tumor-targeted drug delivery with reduced peak-related toxicity, while its prefilled, standardized vials simplify preparation and dosing, offering improved tolerability, suitability for combination therapy, and enhanced treatment workflow across solid tumor and hematologic oncology settings.

In January 2024, CHEPLAPHARM Arzneimittel GmbH, a Germany-based pharmaceutical company, acquired the European rights to Myocet from Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition strengthens CHEPLAPHARM's oncology portfolio through the addition of Myocet, a non-pegylated liposomal doxorubicin formulation, supporting its strategy to integrate established drugs. Teva Pharmaceutical Industries Ltd., based in Israel, provides the liposomal doxorubicin product Myocet.

Major companies operating in the liposomal doxorubicin market are Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Limited, Zydus Lifesciences Ltd., Accord Healthcare Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V., Apotex Inc., Natco Pharma Limited, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd., TTY Biopharm Company Limited, CSPC Pharmaceutical Group Limited, Luye Pharma Group Ltd., Qilu Pharmaceutical Co. Ltd., Chia Tai Tianqing Pharmaceutical Group, SRS Life Sciences.

North America was the largest region in the liposomal doxorubicin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal doxorubicin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liposomal doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liposomal doxorubicin market by increasing costs associated with imported active pharmaceutical ingredients, lipids, and sterile manufacturing inputs. These effects are most evident across branded products such as doxil or caelyx and newer liposomal formulations, particularly in regions like asia-pacific and europe that depend on global pharmaceutical supply chains. Hospitals face higher procurement and treatment costs due to tariff-related pricing pressures. On the positive side, tariffs have encouraged local manufacturing, increased production of generic alternatives, and strengthened regional oncology drug supply resilience.

The liposomal doxorubicin market research report is one of a series of new reports that provides liposomal doxorubicin market statistics, including liposomal doxorubicin industry global market size, regional shares, competitors with a liposomal doxorubicin market share, detailed liposomal doxorubicin market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal doxorubicin industry. This liposomal doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liposomal doxorubicin is a formulation of the chemotherapy drug doxorubicin encapsulated within lipid bilayers, forming microscopic vesicles called liposomes. This encapsulation modifies its pharmacokinetics, enabling prolonged circulation in the bloodstream and targeted accumulation at tumor sites due to enhanced permeability and retention effects. Liposomal doxorubicin is employed to treat multiple cancers, including ovarian cancer, breast cancer, and Kaposi's sarcoma, with potentially lower cardiotoxicity compared to conventional doxorubicin formulations.

The main product types of liposomal doxorubicin include Doxil or Caelyx, Lipodox, Myocet, and others. Doxil, also referred to as Caelyx, is a brand of liposomal doxorubicin used to treat various cancers. The routes of administration include parenteral and others, and its applications cover leukemia, bone sarcoma, breast cancer, endometrial cancer, kidney cancer, multiple myeloma, Kaposi sarcoma, and more. It is utilized by a range of end-users, including hospitals, home care, and others.

The liposomal doxorubicin market consists of sales of Doxil and Lipodox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.